T-DXd with or without neratinib for HER2+ breast cancer brain metastases
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether adding neratinib to T-DXd (trastuzumab deruxtecan) works better than T-DXd alone for women with HER2-positive breast cancer that has spread to the brain. It is for those who have not had these specific drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have HER2-positive breast cancer that has spread to other parts of the body, including the brain.
- You have brain metastases that are either new and not yet treated, or have been previously treated and are stable or growing (but you are not in need of emergency treatment or high doses of steroids).
- You have had 2 or fewer previous cancer treatments for advanced disease, and you have never taken T-DXd (trastuzumab deruxtecan) or neratinib.
- Your major organs (like heart, liver, kidneys, and blood cells) are working well enough to handle the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
This trial tests a combination of a targeted cancer drug (T-DXd) with precise radiation to the brain for people with HER2-positive breast cancer that has spread to the brain. It aims to see if this combination can better control the brain tumors while being safe.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
This trial tests a drug called T-DXd in people with advanced non-squamous lung cancer that has a specific HER2 gene change (mutation) and has spread to the brain but isn't causing symptoms. The goal is to see if the drug can shrink tumors and help control the cancer.
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.